- Home
- PSHG vs HOWL Comparison
PSHG vs HOWL Comparison
Compare PSHG & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | HOWL |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 29.7M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSHG | HOWL |
|---|---|---|
| Price | $2.27 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 132.0K | ★ 348.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.34 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.53 |
| 52 Week High | $2.58 | $2.23 |
Technical Indicators
Market Signals| Indicator | PSHG | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 47.05 |
| Support Level | $1.77 | $0.57 |
| Resistance Level | $2.58 | $0.67 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 50.28 | 45.71 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.